By contrast, patients in subgroup S may benefit from pemetrexed because they have lower expression of TYMS. Thus, the 2 newly identified subgroups of lung adenocarcinoma not only well reflect previously recognized clinical characteristics of lung adenocarcinoma but may also provide guidance for treatment regimens. This evidence concerns the gene TYMS and lung adenocarcinoma.